Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) have received an average recommendation of “Moderate Buy” from the eighteen ratings firms that are presently covering the firm, MarketBeat reports. Two investment analysts have rated the stock with a sell recommendation, one has issued a hold recommendation, twelve have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $110.5455.

A number of equities research analysts have recently weighed in on GPCR shares. HC Wainwright cut their target price on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, June 11th. Canaccord Genuity Group started coverage on shares of Structure Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating and a $101.00 price target for the company. Wall Street Zen lowered shares of Structure Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. Finally, Wolfe Research began coverage on Structure Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock.

Structure Therapeutics Price Performance

Shares of GPCR stock opened at $48.48 on Monday. The stock has a fifty day moving average of $44.34 and a 200 day moving average of $56.45. Structure Therapeutics has a 52 week low of $15.80 and a 52 week high of $94.90. The firm has a market capitalization of $3.45 billion, a price-to-earnings ratio of -55.72 and a beta of -1.50.

Structure Therapeutics (NASDAQ:GPCR) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.39) by $0.04. Equities research analysts anticipate that Structure Therapeutics will post -1.64 earnings per share for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Several hedge funds have recently made changes to their positions in the company. CWM LLC raised its holdings in Structure Therapeutics by 35.2% in the fourth quarter. CWM LLC now owns 480 shares of the company’s stock worth $33,000 after purchasing an additional 125 shares in the last quarter. Sterling Capital Management LLC bought a new stake in shares of Structure Therapeutics during the 1st quarter valued at $28,000. State of Wyoming bought a new stake in shares of Structure Therapeutics during the 2nd quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Structure Therapeutics in the 4th quarter worth about $127,000. Finally, Assetmark Inc. grew its position in shares of Structure Therapeutics by 21.4% in the 1st quarter. Assetmark Inc. now owns 2,544 shares of the company’s stock worth $123,000 after buying an additional 449 shares during the period. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical?stage biotechnology company focused on the discovery and development of oral small?molecule therapies that target G protein?coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.